Earnings ·
Nuvation Bio Inc. reported second quarter 2026 financial results on August 6, 2026, achieving total revenue of $31.7…
NUVB-WTNuvation Bio Inc.
Nuvation Bio Inc. reported second quarter 2026 financial results on August 6, 2026, achieving total revenue of $31.7 million, which included $23.2 million in net product revenue for its ROS1 inhibitor IBTROZI (taletrectinib) and $8.5 million in collaboration and license agreements revenue. The company reported a net loss of $62.8 million, or $(0.18) per share on a basic and diluted basis, compared to a net loss of $59.0 million in the prior year period. Research and development expenses increased to $30.7 million from $27.4 million, while selling, general, and administrative expenses rose to $42.6 million from $38.5 million. As of June 30, 2026, Nuvation Bio held cash, cash equivalents, and marketable securities totaling $661.0 million, with an additional $36.5 million in net proceeds secured in July 2026 from the exercise of convertible senior notes overallotment options. The company operates in the biotechnology industry, focusing on developing oncology therapies.